Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Kazia Therapeutics Ltd ADR (KZIA)
Kazia Therapeutics Ltd ADR (KZIA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,431
  • Shares Outstanding, K 13,876
  • Annual Sales, $ 0 K
  • Annual Income, $ -17,880 K
  • 60-Month Beta 2.15
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.80
Trade KZIA with:

Options Overview Details

View History
  • Implied Volatility 239.22% ( +239.22%)
  • Historical Volatility 75.56%
  • IV Percentile 49%
  • IV Rank 20.32%
  • IV High 961.69% on 12/30/22
  • IV Low 54.93% on 11/16/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 1
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 61
  • Open Int (30-Day) 127

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8484 +31.85%
on 03/17/23
1.2000 -6.78%
on 03/02/23
+0.1986 (+21.59%)
since 02/28/23
3-Month
0.5004 +123.54%
on 12/29/22
1.2000 -6.78%
on 03/02/23
+0.6169 (+122.96%)
since 12/28/22
52-Week
0.5004 +123.54%
on 12/29/22
8.6100 -87.01%
on 04/06/22
-6.7514 (-85.79%)
since 03/28/22

Most Recent Stories

More News
Beat the Market the Zacks Way: Kazia Therapeutics, Uber, Medtronic in Focus

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

ITW : 239.88 (+0.18%)
MDT : 79.18 (+0.14%)
TSCO : 230.39 (-0.02%)
CHD : 86.84 (+0.12%)
ULTA : 536.37 (+1.91%)
OXM : 102.77 (-0.48%)
NOBL : 89.84 (+0.35%)
SWGAY : 16.8100 (-0.30%)
KZIA : 1.1186 (+7.56%)
UBER : 31.19 (+1.04%)
BMWYY : 36.5800 (+2.26%)
Novogen Limited (KZIA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Novogen Limited (KZIA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate...

KZIA : 1.1186 (+7.56%)
KAZIA RAISES A$4.5 MILLION TO PROGRESS R&D PROGRAMS

/PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce a placement...

KZIA : 1.1186 (+7.56%)
KAZIA LAUNCHES PRECLINICAL COLLABORATION WITH QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE AND ANNOUNCES PATENT FILING

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce a collaboration with...

KZIA : 1.1186 (+7.56%)
KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) received a deficiency notification from the Listing Qualifications Staff of the Nasdaq...

KZIA : 1.1186 (+7.56%)
COMPELLING PRECLINICAL DATA FOR KAZIA'S EVT801 PUBLISHED IN PEER-REVIEWED CANCER RESEARCH JOURNAL

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the publication of...

KZIA : 1.1186 (+7.56%)
KAZIA TO PRESENT PAXALISIB DATA IN ADULT AND PEDIATRIC BRAIN CANCER AT SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its...

KZIA : 1.1186 (+7.56%)
KAZIA'S PAXALISIB DEMONSTRATES POSITIVE MONOTHERAPY EFFICACY SIGNALS IN PRECLINICAL MODELS OF MELANOMA

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of...

KZIA : 1.1186 (+7.56%)
Novogen Limited (KZIA) Could Find Support Soon, Here's Why You Should Buy the Stock Now

Novogen Limited (KZIA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean...

KZIA : 1.1186 (+7.56%)
KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT 24th ANNUAL GLOBAL INVESTMENT CONFERENCE

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James...

KZIA : 1.1186 (+7.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Kazia Therapeutics Limited is an oncology-focused biotechnology company. It develops anti-cancer drugs as well as provides pharmaceutical research and development technology solutions. The company's lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being...

See More

Key Turning Points

3rd Resistance Point 1.3291
2nd Resistance Point 1.2595
1st Resistance Point 1.1891
Last Price 1.1186
1st Support Level 1.0491
2nd Support Level 0.9795
3rd Support Level 0.9091

See More

52-Week High 8.6100
Fibonacci 61.8% 5.5121
Fibonacci 50% 4.5552
Fibonacci 38.2% 3.5983
Last Price 1.1186
52-Week Low 0.5004

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar